CYP19A1 and breast carcinoma: The ER+ group is the most common type of breast cancers (accounting for approximately 70% of all breast cancer cases), and endocrine therapies with selective ER modulators (SERMs) or aromatase inhibitors (AIs) have been adopted as the standard adjuvant treatments for ER+ tumors [13], [14].